Back

Simultaneous versus sequential initiation of CKM therapies: an indirect comparison of CONFIDENCE and FIDELITY

30 August 2026 (12:24 - 12:36)
Organised by: Logo
Congress Presentation Part of: Optimising pharmacotherapy in heart failure Aldosterone Antagonists ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor John Ostrominski

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

4 More presentations in this session

Presentation thumbnail
Evaluation of machine learning framework for personalized prediction of benefit from beta-blockers in myocardial infarction with preserved or mildly reduced ejection fraction
Doctor Y. Chen (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
The LUNAR-HF Trial: a randomised comparison of inclisiran versus evolocumab in ischaemic heart failure with reduced ejection fraction
Doctor R. Rascon Sabido (Veracruz, MX)
Abstract Slides Video
Presentation thumbnail
Finerenone-related initial declines in eGFR and urinary biomarkers of tubular injury: mechanistic insights from the FIVE-STAR trial
Doctor M. Vaduganathan (Boston, US)
Abstract Slides Video
Presentation thumbnail
Finerenone and serum sodium in patients with heart failure and mildly reduced or preserved ejection fraction: an analysis of FINEARTS-HF
Doctor R. Ono (Glasgow, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Optimising pharmacotherapy in heart failure
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 12:24 CET
You may be interested in
thumbnail
Congress Presentation
CONFIDENCE: Results by KDIGO risk category
31 August 2025
thumbnail
Congress Session
Fine-tuning patient care: a case-based exploration of finerenone in heart and kidney disease
30 August 2025
thumbnail
Congress Presentation
Towards the cure of CKD in T2DM: are we ready to implement four foundational therapies? - pro
30 August 2024
thumbnail
Congress Presentation
Real-world effectiveness and safety of finerenone in patients with chronic kidney disease and type 2 diabetes in the United States: A FOUNTAIN platform analysis
29 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources